Circular RNA Therapeutics Market Report – Research, Industry Analysis Reports and Market Demands

Global Circular RNA Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Circular RNA Therapeutics Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Circular RNA Therapeutics by Company Revenue
- 3.2.2 Top 3 Circular RNA Therapeutics Players Market Share in 2025
- 3.2.3 Top 6 Circular RNA Therapeutics Players Market Share in 2025
3.3 Circular RNA Therapeutics Market: Overall Company Footprint Analysis
- 3.3.1 Circular RNA Therapeutics Market: Region Footprint
- 3.3.2 Circular RNA Therapeutics Market: Company Product Type Footprint
- 3.3.3 Circular RNA Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Circular RNA Therapeutics Consumption Value and Market Share by Type (2021-2026)
4.2 Global Circular RNA Therapeutics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Circular RNA Therapeutics Consumption Value Market Share by Application (2021-2026)
5.2 Global Circular RNA Therapeutics Market Forecast by Application (2027-2032)

6 North America

6.1 North America Circular RNA Therapeutics Consumption Value by Type (2021-2032)
6.2 North America Circular RNA Therapeutics Market Size by Application (2021-2032)
6.3 North America Circular RNA Therapeutics Market Size by Country
- 6.3.1 North America Circular RNA Therapeutics Consumption Value by Country (2021-2032)
- 6.3.2 United States Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 6.3.3 Canada Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Circular RNA Therapeutics Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Circular RNA Therapeutics Consumption Value by Type (2021-2032)
7.2 Europe Circular RNA Therapeutics Consumption Value by Application (2021-2032)
7.3 Europe Circular RNA Therapeutics Market Size by Country
- 7.3.1 Europe Circular RNA Therapeutics Consumption Value by Country (2021-2032)
- 7.3.2 Germany Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 7.3.3 France Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 7.3.5 Russia Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 7.3.6 Italy Circular RNA Therapeutics Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Circular RNA Therapeutics Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Circular RNA Therapeutics Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Circular RNA Therapeutics Market Size by Region
- 8.3.1 Asia-Pacific Circular RNA Therapeutics Consumption Value by Region (2021-2032)
- 8.3.2 China Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 8.3.3 Japan Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 8.3.5 India Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 8.3.7 Australia Circular RNA Therapeutics Market Size and Forecast (2021-2032)

9 South America

9.1 South America Circular RNA Therapeutics Consumption Value by Type (2021-2032)
9.2 South America Circular RNA Therapeutics Consumption Value by Application (2021-2032)
9.3 South America Circular RNA Therapeutics Market Size by Country
- 9.3.1 South America Circular RNA Therapeutics Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Circular RNA Therapeutics Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Circular RNA Therapeutics Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Circular RNA Therapeutics Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Circular RNA Therapeutics Market Size by Country
- 10.3.1 Middle East & Africa Circular RNA Therapeutics Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Circular RNA Therapeutics Market Size and Forecast (2021-2032)
- 10.3.4 UAE Circular RNA Therapeutics Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Circular RNA Therapeutics Market Drivers
11.2 Circular RNA Therapeutics Market Restraints
11.3 Circular RNA Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Circular RNA Therapeutics Industry Chain
12.2 Circular RNA Therapeutics Upstream Analysis
12.3 Circular RNA Therapeutics Midstream Analysis
12.4 Circular RNA Therapeutics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Circular RNA Therapeutics market size was valued at US$ 49.39 million in 2025 and is forecast to a readjusted size of US$ 503 million by 2032 with a CAGR of 38.6% during review period.
Circular RNA therapeutics represent an emerging RNA treatment modality that uses engineered circular RNA as a direct therapeutic molecule, a protein-expression vehicle, or an in vivo functional regulatory tool. Candidate therapies are generally developed through sequence design, in vitro transcription, RNA circularization, purification, delivery formulation development, and GMP-compliant scale-up manufacturing. Key applications include therapeutic vaccines, protein-expression therapies, in vivo CAR-T, cancer immunotherapy, ischemic tissue repair, genetic diseases, and rare diseases. Upstream inputs mainly include nucleotide raw materials, modified nucleosides, enzymes, plasmid templates, buffers, chromatography media, single-use bioprocessing consumables, lipid nanoparticle materials, viral vectors, analytical reagents, and sterile filling and packaging materials. Downstream customers mainly include innovative biotechnology companies, RNA therapeutic platform developers, vaccine companies, large pharmaceutical companies, CROs, CDMOs, and hospital-based clinical research centers.
The circular RNA therapeutics market remains at an early stage of clinical translation, with industry activity concentrated on platform validation, candidate selection, circularization process optimization, delivery system development, clinical material manufacturing, and safety evaluation. The sector has not yet established stable commercial drug sales, and company value is primarily reflected in patent portfolios, technology platforms, pipeline progress, delivery capabilities, manufacturing scalability, and external partnerships. The number of global companies with clearly disclosed platforms and active development programs remains limited, with the strongest concentrations in the United States and China. European participation is more visible in vector-mediated circular RNA expression systems. Considerable differences remain among direct RNA delivery, lipid nanoparticle delivery, local injection, viral vector delivery, and intracellular circularization approaches, and no single technology architecture has yet become dominant.
Future market development will be driven by the transition from platform proof of concept to integrated validation of clinical efficacy, human safety, and manufacturing feasibility. Early companies have emphasized the potential advantages of circular RNA in molecular stability, expression durability, and programmability, while future competition will increasingly focus on translation efficiency, dose-response relationships, innate immune activation, tissue selectivity, and repeat-dose feasibility. As more candidates enter human trials, the industry is expected to develop product clusters around therapeutic vaccines, in vivo cell reprogramming, localized tissue repair, protein replacement, and genetic disease treatment. Directly delivered circular RNA therapies and vector-mediated expression therapies are likely to coexist, serving different tissues, dosing schedules, and required expression durations.
Market growth is primarily supported by continued innovation in RNA therapeutics, unmet clinical needs, advances in delivery materials, large-pharma collaboration, and accumulating clinical development experience. Compared with linear mRNA, circular RNA may provide a longer protein-expression window in selected applications and potentially reduce the need for frequent dosing. This creates differentiated opportunities in localized sustained expression, long-term protein supplementation, and in vivo immune-cell reprogramming. Oncology, autoimmune disease, ischemic cardiovascular disease, infectious disease, and rare genetic disease are likely to remain key early validation areas. Research agreements, technology licensing, and acquisition activity involving large pharmaceutical companies may provide emerging platform developers with funding, clinical development capabilities, global regulatory resources, and manufacturing support.
The main barriers are the limited maturity of the technology, the absence of established clinical differentiation, and uncertainty regarding industrialization pathways. Although circular RNA may offer improved molecular stability, its actual in vivo translation efficiency, immunogenicity, delivery performance, expression control, and long-term safety require further human evidence. Manufacturing also faces challenges involving circularization yield, removal of residual linear RNA and double-stranded RNA impurities, batch consistency, quality standard development, analytical method validation, and production cost control. Different circularization and delivery approaches may be subject to different regulatory expectations, increasing the complexity of clinical filing and quality control. In the near term, the industry is therefore expected to remain R&D-intensive, with substantial project differentiation, high clinical attrition, and volatile revenue generation.
This report is a detailed and comprehensive analysis for global Circular RNA Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Circular RNA Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global Circular RNA Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Circular RNA Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Circular RNA Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Circular RNA Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Circular RNA Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Orna Therapeutics, RiboX Therapeutics, Sail Biomedicines, Chimerna Therapeutics, Torque Bio, Circurna, Shanghai CirCode Biomed, Therorna, Circio Holding, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Circular RNA Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Protein Expression Therapeutics
Therapeutic Vaccines
Other
Market segment by Delivery Technology
Lipid Nanoparticle Delivery
Local Direct Delivery
Other
Market segment by Route of Administration
Intravenous Administration
Local Injection
Other
Market segment by Application
Pharmaceutical and Biotechnology Companies
Research Institutes
Other
Market segment by players, this report covers
Orna Therapeutics
RiboX Therapeutics
Sail Biomedicines
Chimerna Therapeutics
Torque Bio
Circurna
Shanghai CirCode Biomed
Therorna
Circio Holding
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Circular RNA Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Circular RNA Therapeutics, with revenue, gross margin, and global market share of Circular RNA Therapeutics from 2021 to 2026.
Chapter 3, the Circular RNA Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Circular RNA Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Circular RNA Therapeutics.
Chapter 13, to describe Circular RNA Therapeutics research findings and conclusion.

Buy now